Supportive treatments

Denosumab for myeloma bone disease: ready for prime time? Dimopoulos MA et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30075-5. doi: 10.1016/S1470-2045(18)30075-5. [Epub ahead of print]. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Raje N et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30072-X. doi: 10.1016/S1470-2045(18)30072-X. [Epub ahead of…

General

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Frerichs KA et al.Expert Rev Clin Immunol. 2018 Feb 21. doi: 10.1080/1744666X.2018.1443809. [Epub ahead of print]. Multinucleated giant myeloma cells after failure of daratumumab therapy. Guijarro F et al. Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15139. [Epub ahead of print]. Defining a set of standardised outcome measures for newly diagnosed patients…

Emerging treatments

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. Pulte ED et al. Oncologist. 2018 Feb 7. pii: theoncologist.2017-0440. doi: 10.1634/theoncologist.2017-0440. [Epub ahead of print]. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Richardson PG et al. Br J Haematol. 2018 Feb 13. doi: 10.1111/bjh.15058. [Epub…

Diagnostic techniques and prognostic indicators

Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Pan Y et al.Clin Chim Acta. 2018 Feb 19;480:199-205. doi: 10.1016/j.cca.2018.02.019. [Epub ahead of print]. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple MyelomaWith Deep Responses. Miyazaki K et al. Clin Lymphoma Myeloma Leuk. 2018 Feb 19. pii: S2152-2650(17)31288-0. doi: 10.1016/j.clml.2018.01.008.…

Current treatments

Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Tanimura A et al. Int J Hematol. 2018 Jan 31. doi: 10.1007/s12185-018-2408-4. [Epub ahead of print]. Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ et al. Biol Blood…

Complications of myeloma and its treatments

Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Shah C et al. Leuk Lymphoma. 2018 Feb 21:1-13. doi: 10.1080/10428194.2018.1437269. [Epub ahead of print]. Acquired factor V deficiency in a patient with myeloma and amyloidosis. Quek JKS et al. Thromb Res. 2018 Jan 31;164:1-3. doi: 10.1016/j.thromres.2018.01.045. [Epub ahead of print]. Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. Lavi N et…

Biology and genetics

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Gralewski JH et al. Diagn Pathol. 2018 Feb 20;13(1):15. doi: 10.1186/s13000-018-0692-1. The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor. Du Y et al. J Biol Chem. 2018 Feb 21. pii: jbc.RA117.000972. doi: 10.1074/jbc.RA117.000972. [Epub ahead of print]. Loss of heterozygosity…

Results from Phase III ALCYONE trial published

The results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…

Phase III pomalidomide trial reaches primary endpoint

Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…